Morepen Laboratories is all set to gain from the 180 day marketing exclusivity recently granted to Geneva Pharmaceuticals Inc for Loratadine in the U S, according to Bombay Stock Exchange.

Morepen Lab has an exclusive arrangement with Geneva Pharma and is the sole supplier for bulk Loratadine to Geneva Pharma. Geneva (the generic name arm of Novartis AG) has already launched its generic version of Claritin in the US market on January 23 and the exclusivity will be for six months from the date of launch of the drug.

The innovator of the $3.20 million drug, Schering Plough owns the brand Claritin. Morepen expects to generate additional revenue of around $20 million (RS 100 crore) during the period of exclusivity and net profit during this period is expected to get an additional boost of around $10-12 million (Rs 50-60 crore). Morepen is flushed with orders and has already received orders worth $ 10 million after the grant of exclusivity to Geneva Pharma, which will be shipped over the next two-three months.